290O - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant:…
jwood@krftwrk.caNovember 14, 2018
LBA50 - Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III…
jwood@krftwrk.caNovember 14, 2018
LBA67 - Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: a French Sarcoma Group…
jwood@krftwrk.caNovember 14, 2018
Biologic therapy has revolutionized the treatment of IBD and improved patient outcomes drastically. Many of…
jwood@krftwrk.caDecember 13, 2016
